Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$6.52 - $8.05 $749,936 - $925,919
115,021 New
115,021 $823,000
Q3 2022

Nov 14, 2022

BUY
$7.57 - $12.5 $67,388 - $111,275
8,902 Added 8.47%
114,012 $883,000
Q2 2022

Aug 15, 2022

SELL
$5.04 - $9.48 $163,512 - $307,559
-32,443 Reduced 23.59%
105,110 $804,000
Q1 2022

May 11, 2022

SELL
$7.09 - $89.45 $3,637 - $45,887
-513 Reduced 0.37%
137,553 $1.06 Million
Q4 2021

Feb 11, 2022

BUY
$80.85 - $128.49 $25,872 - $41,116
320 Added 0.23%
138,066 $11.7 Million
Q3 2021

Nov 12, 2021

BUY
$81.97 - $106.94 $835,602 - $1.09 Million
10,194 Added 7.99%
137,746 $13.2 Million
Q2 2021

Aug 11, 2021

BUY
$77.2 - $126.54 $260,858 - $427,578
3,379 Added 2.72%
127,552 $11.9 Million
Q1 2021

May 13, 2021

SELL
$110.45 - $164.47 $1.09 Million - $1.62 Million
-9,861 Reduced 7.36%
124,173 $14.1 Million
Q4 2020

Feb 09, 2021

BUY
$60.78 - $154.03 $1.57 Million - $3.98 Million
25,861 Added 23.91%
134,034 $19.7 Million
Q3 2020

Nov 12, 2020

SELL
$45.05 - $59.27 $148,755 - $195,709
-3,302 Reduced 2.96%
108,173 $6.4 Million
Q2 2020

Aug 12, 2020

BUY
$42.74 - $66.25 $180,234 - $279,376
4,217 Added 3.93%
111,475 $6.03 Million
Q1 2020

May 06, 2020

BUY
$38.18 - $73.95 $499,050 - $966,600
13,071 Added 13.88%
107,258 $5.12 Million
Q4 2019

Feb 14, 2020

BUY
$13.9 - $76.65 $470,362 - $2.59 Million
33,839 Added 56.07%
94,187 $6.78 Million
Q3 2019

Nov 07, 2019

SELL
$10.24 - $17.57 $1,085 - $1,862
-106 Reduced 0.18%
60,348 $867,000
Q2 2019

Aug 12, 2019

BUY
$6.2 - $12.0 $207,898 - $402,384
33,532 Added 124.55%
60,454 $707,000
Q1 2019

May 14, 2019

BUY
$6.43 - $9.44 $87,840 - $128,959
13,661 Added 103.02%
26,922 $175,000
Q4 2018

Feb 11, 2019

BUY
$6.11 - $10.43 $81,024 - $138,312
13,261 New
13,261 $94,000

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $455M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.